Loading
A phase 2 trial of PF-08634404, Bevacizumab, CAPOX in colorectal cancer, run by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., now recruiting.
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT06493760 by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., with 130 participants planned, started 2024-09-03 and due to reach its primary completion in 2025-06. Interventions recorded: SSGJ-707, Bevacizumab, Oxaliplatin, Capecitabine, Calcium Folinate. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Capecitabine, Colorectal cancer.
Shares PF-08634404, Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Bevacizumab.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares Leucovorin (folinic acid), Bevacizumab, Capecitabine.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Capecitabine.